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Introduction
Hip fragility fractures constitute a major clinical and
economic burden worldwide. These fractures are
considered amongst the most fatal fractures for elderly
people and can potentially result in impaired functioning
with increased morbidity and mortality.1 This challenges
the clinicians in identifying patients at risk of worse
outcome in order to optimise and intensify treatment in
these patients. Conventional risk factors for osteoporosis
include advancing age, female gender, smoking, alcohol
intake, physical inactivity, low body mass index (BMI),
steroid use, and low calcium and vitamin D intake. A
variety of factors including pre-fracture functional and
health status, anaemia and age have shown to influence
patient outcome.
Fragility fractures are a strong indicator of underlying
osteoporosis and provide an opportunity for their
appropriate management, including osteoporosis
assessment and treatment, in order to prevent future
fractures. Current evidence-based guidelines for
osteoporosis recommend vitamin D sufficiency as the
initial mainstay of osteoporotic fracture prevention.
However, more than two-third patients with such
fractures do not receive osteoporosis evaluation and
treatment.2
It is well known that patients who suffer a hip fracture are
two to four times more likely to have a recurrent fracture.3
More than 40% hip fracture patients were reported to
have sustained another osteoporotic fracture in the
preceding years.4 Despite that, in the United States only 2
% of all hip fracture patients are prescribed ideal drug
therapy, including calcium, vitamin D3 and an anti-
resorptive or bone-forming medication.5 Data from Italy
shows that 78% of patients received a medication for
osteoporosis after a hip fracture6 whereas data from
Netherlands shows that only 19% women beyond 50
years of age were treated with medications for
osteoporosis in the year after a low-trauma fracture.7 In
Belgium only 6% postmenopausal women received a
bisphosphonate or hormone therapy after a hip fracture.8
Studies from Germany and Sweden showed that only 11-
16% of all female patients and 3.4% of male patients with
osteoporosis are currently receiving an appropriate anti-
resorptive or bone-forming treatment.9,10
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Abstract
Objective: To assess the burden of anaemia and osteoporosis in hip fracture patients, to determine the rate of
blood transfusion per-operatively, to assess the use of calcium and vitamin D supplements and the use of anti-
osteoporotic medications postoperatively.
Methods: A retrospective study was conducted at Aga Khan University and Hospital (AKUH) between June 2009
andMay 2011, and comprised record of patients treated for intertrochanteric and femur neck fractures. Patients with
associated pathological, open or long bone fractures were excluded. The main study outcome measures were the
use of pre-operative and post-operative calcium, vitamin D, bisphosphonates and management of anaemia pre-
and post-operatively. Demographic data was also collected including age, gender, and co-morbids. Statistical
analysis was performed using SPSS 19.
Results:Of the 129 patients, 65(50.4%) were women. The overall mean agewas 67.2±15.5 years. Mean pre-operative
haemoglobin level was 12.3±1.5 gm/dl and 39(30%) patients were anaemic, while post-operative haemoglobin was
10.2±1.71 with 90(70%) anaemic patients, but only 14(10.9%) patients received per-operative blood transfusion.
Pre-operative and post-operative vitamin D supplementation was advised in 3(2.3%) and 18(14%) patients
respectively, whereas pre-operative and post-operative bisphosphonate supplementation was advised in 3(2.3%)
and 1(0.8%) patients.
Conclusion: There is a strong need to pay attention to the management of peri-operative anaemia and calcium,
vitamin D and bisphosphonate supplementation in the discharge medications of patients with hip fragility
fractures.
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Literature has shown that haemoglobin levels are related
to outcome of patients with hip fractures. A study
conducted in Japan showed that 72% (92/128) patients
without anaemia were ambulatory compared to 50%
(130/260) patients with anaemia after hip fracture
surgery.11 Another study conducted in New York showed
that hospital length of stay and mortality rate at 6 and 12
months of surgery were significantly higher for patients
who were anaemic on admission.12 One study showed
that anaemia was an independent risk factor for patients
not being able to walk on 3rd post-operative day.13
A retrospective study conducted in Asian countries
among postmenopausal women who suffered a fragility
fracture showed that only 33% received a prescription of
medications to treat osteoporosis after being discharged
from the hospital.14
The present study was conducted to examine the
prescribing practices of orthopaedic surgeons in relation
to insufficiency hip fractures treated at a tertiary care
hospital.
Patients and Methods
A retrospective study was conducted at Aga Khan
University Hospital (AKUH) between June 2009 and May
2011, and comprised record of patients treated for
intertrochanteric and femur neck fractures. Patients with
associated pathological, open or long bone fractures were
excluded as were bed-bound patients. The main study
outcome measures were the use of pre-operative and
post-operative calcium, vitamin D and bisphosphonates,
and the management of anaemia pre- and post-
operatively. Demographic data was also collected,
including age, gender and co-morbids.
Statistical analysis was performed using SPSS 19.
Categorical data was presented as frequency and
percentage, and numerical data as mean and standard
deviation.
Results
A total of 163 patients had been managed for hip
fractures, but 34(21%) had to be excluded for missing
data, and the final study sample was 129(79%) patients.
The mean age was 67.2±15.5 years and 65(50.4%) were
women (Table-1). Besides, 83(64.3%) patients had one or
more comorbidities, the most common being diabetes
mellitus 39(30.2%), hypertension 29(38%) and heart
disease 15(12%). The mean pre-operative haemoglobin
level was 12.3±1.5 gm/dl, and post-operative
haemoglobin was 10.2±1.7. Overall, 39(30%) patients had
anaemia pre-operatively and 90(70%) post-operatively
with only 14(10.9%) (95% confidence interval [CI]: 6.1-
17.5) patients receiving peri-operative blood transfusion.
Pre-operative vitamin D levels were checked in 6(4.7%)
patients (95% CI: 1.7-9.8) either during the current
admission or prior to it, whereas post-operative levels
were checked in 22(17.1%) (95% CI: 11.0-24.7). Pre-
operative and post-operative vitamin D supplementation
were advised in 3(2.3%) (95% CI: 0.5-6.6) and 18(14%)
patients (95% CI: 8.5-21.2), whereas pre-operative and
post-operative bisphosphonate supplementation were
advised to 3(2.3%) (95% CI: 0.5-6.6) and 1(0.8%) patients
(95% CI: 0.02-4.2) (Table-2).
Discussion
According to an estimate, by 2050, 50 per cent of hip
fractures would be occurring in Asia.15 Administration of
zoledronic acid to patients suffering from a low-trauma
hip fracture, two or more weeks after surgical fixation,
increases hip bone mineral density (BMD) and induces
significant reductions in the risk of subsequent clinical
vertebral, non-vertebral and hip fractures.16 There is high
prevalence of osteoporosis in Pakistan with 97% women
aged 75-84 years and 55%women aged 45-54 years being
predisposed to osteoporosis.17 According to a study
conducted on premenopausal healthy women of urban
areas of Pakistan, vitamin D deficiency was present in
82.8% and insufficiency in 16.1% while only 1.1% had
normal vitamin D levels which leads to higher risk of
osteoporosis.18 Another study conducted among
postmenopausal women of rural areas in Pakistan showed
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Table-1: Demographic characteristics.
Age (years) No. %
< 59 29 22.5
60-69 33 25.6
70-79 40 31.0
> 80 27 20.9
Gender
Male 64 49.6
Female 65 50.4
Table-2: Details of 25 hydroxy-Vitamin D blood levels, pre-operative and post-
operative prescriptions of Vitamin D and bisphosphonates.
Variable Number of patients %
Pre-op Vit D levels checked 6 4.7
Post-op Vit D levels checked 22 17.1
Pre-op Vit D supplementation 3 2.3
Post-op Vit D supplementation 18 14.0
Pre-op osteoporosis medications 3 2.3
Post-op osteoporosis medications 1 0.8
that vitamin D deficiency and low intake of dietary
calcium was the main risk factor for osteoporosis. Despite
this, our study showed that pre- and post-operative
vitamin D levels were checked only in 4.7% and 17.1%
patients respectively. Only 2.3% patients were taking
vitamin D pre-operatively and only 14% were advised to
take it post-operatively.
Literature has shown that anaemia adversely affects
ambulatory status as well as length of hospital stay and
mortality of patients after hip fracture surgery.11-13 Our
study showed a 30% pre-operative prevalence of anaemia
and 70% post-operatively with only a 10.9% transfusion
rate.
A retrospective analysis of hip fragility fracture patients
from King Fahad Hospital, Saudi Arabia, showed that post-
surgery 60.8% patients did not receive any osteoporotic
medications.19 Similarly, our study also showed a low
prescription rate of bisphosphonate of 2.3% in pre-
operative patients and 0.8% in post-operative patients.
Patients after hip fracture surgery are usually discharged
in two weeks from orthopaedic care and in order to
improve the management one way could be to start
osteoporosis treatment before discharge from hospital
along with calcium and vitamin D supplementation.20
Another way could be to work together with family
physicians and strengthen our primary care services for
follow-up of patients with hip fragility fractures and
monitor administration of anti-osteoporotic drugs.
A retrospective cohort study done in tertiary care
hospitals of Ontario which included 354 patients of age
>50 with diagnosis of hip fragility fractures showed that
only 21% were started on anti-bone-resorptive
medications and it was mostly in those who were
transferred to rehabilitation and geriatric units.21 Though
we do not have well developed geriatric and
rehabilitation services, if we work in collaboration with
our family physicians or set upmultidisciplinary clinics, we
can close this gap in continuity of care.
A meta-analysis showed that there was no clinically
detectable delay to fracture-healing following
bisphosphonate treatment and therefore secondary
prevention should be implemented soon after fragility
fracture.22 Other than bisphosphonates, hormonal
options include calcitonin, selective oestrogen receptor
modulators (SERMS), and teriparatide with their specific
clinical indications. A creatinine clearence of lower than
35 ml/min is a contraindication to all available drugs
except denosumab.23 Also, there should be a life
expectancy of at least 6 months to justify beneficial
effects of anti-osteoporotic medications since their effects
are expected months after starting the treatment.
There is strong need to inculcate peri-operative
management of anaemia, and calcium and vitamin D
supplementation in the discharge medications of patients
with hip fragility fractures. Osteoporosis diagnosis and
management should also be part of this treatment
protocol. These pathways could also be considered for
other fragility fractures.
Conclusion
Correction of anaemia, Vitamin D and calcium
supplementation, in addition to anti-osteoporosis
treatment after surgery or conservative treatment can
ensure optimal recovery and survival, especially in hip
fracture patients.
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